Latest Articles

Publication Date
Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer - OncLive

Cadonilimab Plus Chemotherapy Shows Strong Efficacy and Safety in Advanced or Recurrent Endometrial Cancer OncLive

Published: April 12, 2026, 2:35 p.m.
Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.

Ovarian clear cell carcinoma (OCCC) is an endometriosis-associated ovarian cancer subtype. Somatic mutations in OCCC are reported in ARID1A, PIK3CA, and the TERT promoter (TERTp), as well as less commonly …

Published: April 10, 2026, midnight
Endometriosis and Endometrial Cancer-Association Between Biological Mechanisms and Its Clinical Implications.

Endometriosis and endometrial cancer are distinct gynecological conditions that share overlapping biological mechanisms with implications for clinical management. Endometriosis is a chronic, benign disorder characterized by the ectopic implantation of …

Published: April 10, 2026, midnight
Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report - Cureus

Neoadjuvant Chemotherapy Followed by Radical Cytoreductive Surgery in Serous Endometrial Carcinoma With Inguinal Lymph Node Metastasis: A Case Report Cureus

Published: April 9, 2026, 9:38 a.m.
Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer - epi-phare

Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent dMMR Endometrial Cancer epi-phare

Published: March 9, 2026, 10:32 a.m.
Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. - lamilano.it

Endometrial cancer: AIFA approves immunotherapy with chemotherapy for all patients. lamilano.it

Published: Feb. 23, 2026, 1:30 p.m.
Fertility preservation in women with endometriosis: How, when, and for whom?

Fertility preservation options, including cryopreservation of oocytes, embryos, and ovarian tissue, were initially focused on women undergoing gonadotoxic chemotherapy for oncologic treatment. The indications have expanded to include nonmalignant conditions …

Published: Feb. 20, 2026, midnight
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace

Published: Feb. 4, 2026, 4:47 a.m.
Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer - TradingView

Gsk - Quebec To Reimburse Jemperli Plus Chemotherapy Via Ramq For Primary Advanced/First Recurrent Endometrial Cancer TradingView

Published: Feb. 3, 2026, 1:11 p.m.
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - Newswire Canada

Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer Newswire …

Published: Feb. 3, 2026, 1 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!